Abstract

The case presents the strategies adopted by Lupin Limited to emerge as one of the leading pharmaceutical companies in India. For the fiscal 2004-05, Lupin reported revenues of Rs. 12.12 billion, placing it among the top six companies in the Indian pharma industry. The company aims at achieving the revenues of US$ 1 billion by 2009. To achieve this target, Lupin has made heavy investments in R&D, manufacturing processes and is focusing on exports. Notwithstanding Lupin's success till date and its plans for future growth, the company faces significant threat in the form of product patents, high debts and rising competition from both local and foreign pharma companies. The case highlights the challenges facing Lupin and its plans to overcome these challenges.

Learning Objectives

The case is structured to achieve the following Learning Objectives:

• Growth strategies of Lupin Limited
• Recent trends in Indian Pharmaceutical Industry
• Product patent regime in India.

Keywords

Lupin Limited, Indian Pharmaceutical Industry, Product patent, Process patents, Active pharmaceutical ingredients, Drug price control, Generics, Anti-tuberculosis Drugs, Pediatrics segment, Over-the-counter drugs